Metabolic marker for diagnosing coronary heart disease
A technology of metabolic markers and coronary heart disease, applied in the field of biochemistry, to achieve the effect of promoting standardization, high sensitivity, and improving the convenience of diagnosis
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0027] Example 1: Screening and characterization of plasma differential metabolites between patients with coronary heart disease and patients without coronary heart disease (including healthy people and patients with coronary atherosclerosis)
[0028] 1. Objects and methods
[0029] 1. The source of the specimen
[0030] After obtaining the consent of the patients, the peripheral venous blood plasma of 480 patients with coronary atherosclerosis, 867 patients with coronary heart disease and 350 healthy people in Jiangsu Provincial People's Hospital from September 2010 to June 2015 was collected. Confirmed by coronary angiography. The age and sex of healthy people were matched with patients with coronary atherosclerosis and coronary heart disease. All patients with coronary atherosclerosis, coronary heart disease and healthy people have normal heart, lung, liver, kidney and hematopoietic functions.
[0031] The time of blood collection was in the morning on an empty stomach. ...
Embodiment 2
[0054] Example 2: Construction of ROC curves to compare the ability of 10 differential metabolites to diagnose patients with coronary heart disease and non-coronary heart disease (including healthy people and coronary atherosclerosis)
[0055] Receiver operating curve (ROC) method was used for verification, and the ability to diagnose coronary heart disease was judged by the expression levels of differential metabolites in the plasma of patients with coronary heart disease and non-coronary heart disease (including healthy people and coronary atherosclerosis). . The results showed that 1-palmitoyl-sn-glycerol-3-phosphatidylcholine, 1-stearatetraenoyl-sn-glycerol-3-phosphatidylcholine, 1-linoleoyl-sn-glycerol-3 - Phosphatidylcholine, 1-stearoyl-sn-glycerol-3 phosphatidylcholine, 1-linoleoyl-2-hydroxy-sn-glycerol-3-phosphatidylethanolamine, 1-linolenoyl-sn-glycerol -3-Phosphatidylcholine, 1-oleoyl-sn-glycerol-3-phosphatidylcholine, 1-hexadecenoyl-sn-glycero-3-phosphatidylcholine...
Embodiment 3
[0073] Embodiment 3: application in the screening treatment or the medicine of alleviating coronary heart disease
[0074] The blood plasma of 185 patients with coronary heart disease before and after drug treatment was detected, and the results showed that: with the increase of the course of drug treatment, the patient's condition was gradually relieved, and the levels of 10 metabolic markers provided by the present invention tended to gradually increase in the plasma. It is at the level of healthy people, and there is no significant difference (P>0.05) between the plasma levels of healthy people after complete cure. This result is consistent with the detection results of coronary angiography. Therefore, the metabolic markers provided by the present invention can be used to screen drugs for treating or alleviating coronary heart disease.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com